Meropenem Venus

Meropenem, the active ingredient in Meropenem Venus, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats infections caused by susceptible bacteria in hospitalized patients, including severe intra‑abdominal, urinary tract, and respiratory infections.

GNH USA supplies Meropenem Venus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections.

- Complicated intra‑abdominal infection: provides broad‑spectrum coverage against Gram‑negative, Gram‑positive and anaerobic pathogens. - Complicated urinary tract infection: eradicates resistant Enterobacteriaceae and other uropathogens. - Hospital‑acquired pneumonia: targets multidrug‑resistant organisms including Pseudomonas aeruginosa. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat susceptible meningitis‑causing bacteria. - Sepsis and septic shock: offers rapid bactericidal activity in systemic infections.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis after infusion. - Rash: erythematous skin eruptions. - Headache: transient cranial discomfort. - Phlebitis at injection site: local inflammation.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute hypersensitivity reaction. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Renal toxicity: elevated serum creatinine. - Neutropenia: reduced white blood cell count. - Thrombocytopenia: decreased platelet levels.

Careful assessment is required before initiating therapy. - Renal impairment: adjust dose based on creatinine clearance. - Hypersensitivity: avoid if known allergy to carbapenems or β‑lactams. - Seizure risk: monitor patients with CNS disorders. - Neonates and infants: use only under specialist supervision. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug‑drug interactions should be reviewed.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough. - Concurrent carbapenems: additive toxicity, avoid simultaneous use. - High‑dose aminoglycosides: increased nephrotoxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Warfarin: may enhance anticoagulant effect, check INR. - Oral contraceptives: possible reduction in efficacy, advise alternative contraception.